UnknownNot Applicable

Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial

Italy60 participantsStarted 2020-02-04

Plain-language summary

This is an interventional, open-label, randomized (2:1), standard medical therapy-controlled trial. Subjects in the standard therapy group will be given the opportunity to undergo the active endoscopic treatment after 6 months of follow up (open label extension) if they will not achieve an adequate result on body weight. All patients will be followed until the planned end of the study after 36 months from the ESG procedure. To study the effects of endoscopic gastroplasty on weight, metabolic risk factors, quality of life, satiety, gastrointestinal motility and gut microbiota compared to standard medical treatment control group. Primary endpoint: \- Total body weight loss (%) Secondary endpoints: * Metabolic risk factors (e.g. lipid profile) and anthropometric measurements (e.g hip and waist circumference) * Body composition * Quality of life * Gastroesophageal reflux disease * Non-Alcoholic Fatty Liver Disease (NAFLD) * Non- Alcoholic-Steato-Hepatitis (NASH) * Satiety * Gut microbiota Exploratory endpoints: * Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin * Gastrointestinal motility

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The participants have to fulfill the following criteria for participating in the study: * Age 20 to 65 years * BMI between 30 to 45 kg/m2 * Willingness to participate in the study and ability to comply and understand the study protocol Exclusion Criteria: Active gastric ulcer during the last 6 months * Organic or motility disorder of the stomach and / or esophagus * Anticoagulant treatment * Previous bariatric surgery or any other type of surgery of the esophagus, stomach and duodenum * Ongoing or active malignancy during the last 5 years * Myocardial infarction during the past 6 months or/and heart failure class III or IV according to the New York Heart association's classification * Drug or alcohol abuse * Bulimic or binge eating pattern * Continuous glucocorticoid or anti-inflammatory treatment * Uncontrolled thyroid disease * Pregnancy, breastfeeding * Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study * Hiatal hernia \> 5 cm * Currently participating in other study * Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator

What they're measuring

Total body weight loss

Timeframe: 12 months

Total body weight loss

Timeframe: 36 months

Trial details

NCT IDNCT04200144

SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-02

Contact for this trial

Ivo Boskoski, MD, PhD

+390630156580 ivo.boskoski@policlinicogemelli.it